[MP-202416] Lurbinectedin (SCLC)
Project no.:
MP-202416
Report type:
Status:
Commission work started
Department/Division:
Drug Assessment
Topic:
Cancer
Indication:
Maintenance treatment of adult patients with extensive-stage small cell lung cancer (ESSCLC)
Note:
This Joint Clinical Assessment (JCA) is being conducted in cooperation with Infarmed (National Authority of Medicines and Health Products) Portugal.
Further background information can be found here: European health technology assessment
| Stage | Date |
|---|---|
| 2nd quarter, 2025 | |
| 3rd quarter, 2026 |